PLANO, Texas, July 30, 2026
U.S. Renal Care (USRC) is expanding the availability of medium cut-off (MCO) dialyzers to support Expanded Hemodialysis (HDx) for eligible patients with end-stage kidney disease, advancing access to a dialysis approach designed to improve clearance of middle molecules compared with conventional high-flux hemodialysis. The kidney care provider said the expansion is supported by a growing body of clinical evidence indicating that HDx with MCO dialyzers may provide benefits across patient outcomes and quality-of-life measures, including sleep, post-treatment recovery, cognitive function, itching and restless legs. MCO dialyzers are currently available at selected U.S. Renal Care and Satellite Healthcare centers, with broader availability planned across additional locations. The initiative follows new evidence presented at the 2026 European Renal Association meeting, including findings from the MOTheR trial and CONCORDIA study examining clinical outcomes associated with HDx.
HDx Technology Targets Enhanced Middle Molecule Clearance
Expanded Hemodialysis uses medium cut-off dialyzers on standard dialysis machines to increase clearance of middle molecules compared with conventional high-flux hemodialysis. While standard high-flux dialysis effectively removes smaller solutes, its ability to eliminate larger middle molecules is more limited. These molecules have been associated with inflammation, cardiovascular complications and reduced quality of life among patients receiving maintenance dialysis. MCO dialyzers, including Theranova and ELISIO-HX, incorporate next-generation membranes featuring larger and more uniform pores that expand the range of solute removal. According to U.S. Renal Care, the technology enables clearance of molecules up to approximately 60 kDa and, for several clinically relevant middle molecules, may achieve performance comparable to high-volume hemodiafiltration while avoiding the additional infrastructure and technical complexity required for online HDF. Importantly, HDx can be delivered using existing hemodialysis equipment, potentially making enhanced middle-molecule clearance more accessible across dialysis centers.
Clinical Evidence Supports Expanded Hemodialysis Approach
Recent clinical evidence has strengthened interest in HDx as an advanced approach to maintenance hemodialysis. Results from the randomized MOTheR trial presented at the 2026 European Renal Association meeting compared HDx using MCO dialyzers with online hemodiafiltration and met its primary noninferiority endpoint for a composite of all-cause mortality and major cardiovascular events, according to the announcement. Serious adverse event rates were reported as similar between the treatment groups. Interim findings from the CONCORDIA real-world observational analysis also reported comparable survival outcomes between HDx and HDF. Additional studies cited by U.S. Renal Care suggest potential benefits involving patient-reported symptom burden, including improvements in energy, sleep quality, pruritus, pain, mood, restless legs and post-dialysis recovery time. Research has also examined preservation of residual kidney function, albumin stability and potential hospitalization and healthcare cost outcomes. U.S. Renal Care emphasized that it plans to continue evaluating clinical outcomes through prospectively designed registries to further strengthen the evidence comparing HDx with standard high-flux hemodialysis.
Advertisement
U.S. Renal Care Broadens Access to MCO Dialyzers
The expanded availability of MCO dialyzers represents part of U.S. Renal Care’s broader strategy to integrate evidence-supported dialysis innovation into kidney care. The company provides care to more than 37,000 people living with kidney disease across 32 states, offering both in-center and home dialysis services. By increasing access to MCO technology, USRC aims to provide eligible patients with an additional treatment approach that can enhance middle-molecule removal without requiring the infrastructure associated with online hemodiafiltration. The company’s Kidney Research team also conducts academic collaborations, investigator-initiated studies, industry-sponsored clinical research and federally funded research, supporting continued evaluation of emerging kidney-care technologies. For patients with end-stage kidney disease requiring long-term hemodialysis, treatment effectiveness extends beyond conventional measures of small-solute clearance to include symptom burden, cardiovascular health, recovery and overall quality of life. The growing clinical evidence surrounding Expanded Hemodialysis and medium cut-off membranes may therefore represent an important evolution in dialysis technology, particularly if future prospective evidence continues to demonstrate meaningful clinical and patient-reported benefits. As broader availability reaches additional centers, U.S. Renal Care plans to continue collecting outcomes data to assess how HDx compares with conventional high-flux hemodialysis in routine kidney care.
Source: U.S. Renal Care press release
